sur GENFIT (EPA:GNFT)
GENFIT Releases 2025 Extra-Financial Performance Report for 2024
GENFIT, a biopharmaceutical company focusing on severe liver diseases, announced its 2025 Extra-Financial Performance Report for the fiscal year 2024. This report marks the company's continued commitment to sustainability and corporate social responsibility. Initiated in 2022, the report aims to address the growing interest from various stakeholders.
Pascal Prigent, CEO, highlighted that sustainable development is ingrained in GENFIT's culture. The establishment of an ESG Committee in 2021 has formalized this approach, ensuring structured processes are in place. GENFIT focuses on maximizing the impact of its initiatives, building trust with patients, regulators, and investors.
In 2024, GENFIT emphasized social responsibility through patient engagement and gender equality assessments. The company prepared for the European Corporate Sustainability Reporting Directive but adjusted plans due to regulatory changes in 2025.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de GENFIT